Multilineage dysplasia as assessed by immunophenotype in acute myeloid leukaemia, a prognostic tool in the genetically undefined category

Main Article Content

Yashodha D

Keywords

Acute myeloid leukaemia; Multilineage Dysplasia; Immune-phenotypic score; India

Abstract

Acute myeloid leukaemia (AML) is a type of cancer in which abundance of abnormal blood cells is produced by bone marrow. In India, 1-2 persons per 100,000 people are affected by AML each year. The present research has been carried out on individuals who were suffering from AML and diagnosed with MLD using morphological, immunophenotypic, and molecular criteria. Samples were gathered from the Government Cancer hospitals’ Oncology departments in Bangalore, India. For the trial, a total of 300 participants were enrolled. The observed association with morphology confirmed the capacity of MFC-based approach to draw attention to dysplasia. Insight into the prognosis was limited when looking at MLD data evaluated by an immune-phenotypic score (IPS) either globally or within the narrowly defined genetic groupings. It's interesting to note that IPS-related dysplasia gave critical predictive information while focusing on the genetically undefinable patients who tested triple-negative for FLT3, NPM1, and CEBPA (TN-AML-MLD). While there is no significant correlation between IPS scores and age (p 0.09) or gender (male p 0.67 & female p 0.77), the dysplasia lineage was significantly higher in the absence of dysplastic characteristics (IPS_0), WBC (p 0.01), neutrophile (p 0.01), & platelet (p 0.04). In the ever-changing AML-MLD treatment environment, the influence of the IPS category preserved its validity and gave insight into the prediction of responses.

Abstract 61 | pdf Downloads 94

References

1. Weinberg, O.K.; Seetharam, M.; Ren, L Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood 2009, 113, 1906–1908. [CrossRef] [PubMed]
2. Rozman, M.; Navarro, J.-T.; Arenillas, L.; et al. Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM. Ann. Hematol. 2014, 93, 1695–1703. [CrossRef]
3. Falini,B.; Macijewski,K.; Weiss,T.; Bacher,U.; et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood 2010, 115, 3776–3786. [CrossRef]
4. Vardiman, J.W.; Thiele, J.; Arber, D.A.; et al. The 2008 revision of the World Health Organization ( WHO ) classification of myeloid neoplasms and acute leukemia: Rationale andimportant changes. Blood 2009, 114, 937–951. [CrossRef] [PubMed]
5. Arber, D.A.; Orazi, A.; Hasserjian, R.; Thiele, J The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016, 127, 2391–2405. [CrossRef] [PubMed]
6. Wandt, H.; Schäkel, U.; Kroschinsky, F.; MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood 2008, 111, 1855–1861. [CrossRef] [PubMed]
7. Indian Council of Medical Research; Prepared as an outcome of ICMR Subcommittee on Acute Myeloid Leukemia (AML), Population-based Cancer Registry for Delhi,(2019)
8. Orathai Promsuwicha, Utilization of a Scoring System for Diagnosis of Chronic Lymphocytic Leukemia in Thai Patients; J Med Assoc Thai 2011; 94 (Suppl. 1): S232-S238